Tarsus Pharmaceuticals to acquire Alkeus in US$800M deal to expand ophthalmology pipeline

USA— Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals in a deal worth up to US$800 million, strengthening its ophthalmology portfolio with a promising late-stage treatment for Stargardt disease.

The acquisition is expected to expand Tarsus’ pipeline of eye disease therapies and reinforce its position in the competitive ophthalmic market.

Under the terms of the agreement, Tarsus will pay US$450 million upfront, comprising US$270 million in cash and US$180 million in Tarsus common stock.

Alkeus shareholders may also receive up to US$350 million in additional payments tied to regulatory approvals and commercial milestones.

Once completed, the acquisition will bring Alkeus’ ophthalmology pipeline under Tarsus’ ownership.

Gildeuretinol leads the acquisition

The centerpiece of the deal is gildeuretinol, formerly known as ALK-001, a once-daily oral therapy under development for Stargardt disease, a rare inherited retinal disorder.

Alkeus is currently evaluating the candidate in the pivotal Phase III NORTHSTAR trial (NCT07419334), which enrolled its first patient in June 2026.

The company expects to report topline results during the second half of 2029.

If regulators approve the therapy, gildeuretinol could become one of the first medicines available for Stargardt disease, an area that currently lacks any approved treatment.

The condition affects approximately one in every 10,000 people and gradually damages central vision due to the accumulation of lipofuscin, a toxic yellow-brown pigment, in the retina.

Unlike treatments that primarily target symptoms, gildeuretinol aims to address the disease’s underlying biology.

The therapy works by reducing the formation of toxic vitamin A dimers while preserving the normal visual cycle, a mechanism designed to slow retinal damage and vision loss.

Strengthening Tarsus’ ophthalmology ambitions

Tarsus said the acquisition represents another important step in its strategy to become a leading ophthalmology company.

The transaction follows the company’s earlier US$565 million acquisition of iRenix Medical and its ocular antiseptic candidate, IRX-101, further expanding its eye care portfolio.

By adding gildeuretinol to its pipeline, Tarsus positions itself in one of ophthalmology’s most closely watched therapeutic areas.

Although no treatment has yet secured regulatory approval for Stargardt disease, several biotechnology companies are racing to bring the first therapy to market.

Competition intensifies in Stargardt disease

Among the leading competitors is Belite Bio, which has already begun a rolling New Drug Application (NDA) submission to the US Food and Drug Administration for its Stargardt candidate, tinlarebant.

The company initiated the submission in April 2026 after the retinol-binding protein 4 (RBP4) antagonist achieved positive results in the pivotal Phase III DRAGON study (NCT05244304).

Meanwhile, Ocugen continues to advance its gene therapy candidate, OCU410ST, through late-stage clinical development.

In its second-quarter business update, the company said it remains on schedule to report topline Phase III data during the second quarter of 2027.

Nanoscope Therapeutics is also pursuing the indication with its investigational gene therapy MCO-010.

The company recently advanced the programme into Phase III development after the therapy significantly improved vision in patients enrolled in the Phase II STARLIGHT study (NCT05417126).

Industry analysts expect competition in the Stargardt disease market to intensify as more late-stage candidates approach regulatory review.